REG - N4 Pharma PLC - Result of General Meeting

N4 PharmaAnnouncement

22/04/2025 12:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250422:nRSV6946Fa&default-theme=true

RNS Number : 6946F  N4 Pharma PLC  22 April 2025

 

22 April 2025

 

N4 Pharma plc

 

 ("N4 Pharma" or the "Company")

 

Result of General Meeting

 

N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary
gene delivery system to enable advanced therapies for cancer and other
diseases, is pleased to announce that at the General Meeting ("GM"), held
earlier today, all resolutions were duly passed.

 

The full text of all the resolutions can be found in the Notice of GM, a copy
of which is available on the Company's website.

 

As a result of the passing of the resolutions, the Company has issued the
294,719,650 shares (the "Second Issue Shares"), the Fundraise Warrants and the
Broker Warrants referred to in its announcement dated 1 April 2025.

 

Admission and Total Voting Rights

 

Application has been made to the London Stock Exchange for the Second Issue
Shares to be admitted to trading on AIM, and it is expected that admission
will become effective and trading will commence in the Second Issue Shares at
8.00 a.m. on or around 23 April 2025 ("Admission").

 

Following Admission, the total number of Ordinary Shares in the Company in
issue will be 832,280,349. No shares are held in treasury, therefore the total
number of voting rights in the Company following Admission will be 832,280,349
("Total Voting Rights"). The Total Voting Rights may be used by shareholders
as the denominator for the calculations by which they will determine if they
are required to notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure and Transparency Rules.

 

Capitalised terms used but not otherwise defined in this announcement shall
have the meanings ascribed to such terms in the announcement dated 1 April
2025, unless the context requires otherwise.

 

-      Ends -

 

For more information please contact:

 

 N4 Pharma plc

 Nigel Theobald, CEO                                                       Via N4 Pharma Investor Hub: investors.n4pharma.com

                                                                         (https://investors.n4pharma.com/)
 Luke Cairns, Executive Director

                                                                         https://investors.n4pharma.com/link/0rJWRP
 Submit your questions directly to the management team via the N4 Pharma
 Investor Hub

 SP Angel Corporate Finance LLP                                            Tel: +44 (0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Jen Clarke (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 Turner Pope Investments (TPI) Limited                                     Tel: +44 (0)20 3657 0050

 Joint Broker

 Andy Thacker

 James Pope
 Northstar Communications Limited                                          Tel: +44 (0)113 730 3896

 Investor Relations

 Sarah Hollins

 

About N4 Pharma

N4 Pharma is a pre-clinical biotech company developing Nuvec®, its
proprietary gene delivery system, to enable advanced therapies for cancer and
other diseases.

 

RNA therapeutics are set to impact the treatment of a wide range of diseases
and Nuvec® has several key advantages for RNA gene delivery including the
ability to deliver multiple RNA therapies in a single particle, ease of
manufacturing, protection of the RNA payload to allow for oral delivery, no
unwanted immune response and excellent stability and storage.

 

N4 Pharma is building out its preclinical data set, and working towards
first-in-human clinical data, to support significant licensing deals for its
Nuvec® platform with gene therapy partners.

 

N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for
IBD which serves as a proof-of-concept programme showcasing all the benefits
of the Nuvec® platform.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at
https://investors.n4pharma.com/auth/signup
(https://investors.n4pharma.com/auth/signup) .

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ROMPPUCACUPAGUP